Bispecific Antibodies Latch Onto Advances – Module 1
Released On
March 13, 2023
Expires On
March 12, 2024
Media Type
Internet
Completion Time
30 minutes
Specialty
Geriatric Medicine, Hematology-Oncology
Topic(s)
Lymphoma, Multiple Myeloma, Oncology, Pharmacology
This activity is jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.
The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.
Credit Available
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Program Overview
This activity provides an overview of data for new and emerging T-cell directed bispecific antibodies in the management of hematologic malignancies, with a focus on multiple myeloma.
Learning Objective
Upon completion of this activity, participants should be better able to:
- Analyze available data on bispecific antibodies for the treatment of multiple myeloma
Faculty
Saad Z. Usmani, MD, MBA, FACP
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY
Saad Z. Usmani, MD, MBA, FACP, is the chief of Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, NY. Dr Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He then completed his residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, MI and his fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, CT. Dr Usmani is board certified in internal medicine, hematology, and medical oncology.
Dr Usmani, who is active in clinical and translational research, is focused on plasma cell disorders – in particular, high-risk multiple myeloma. He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group, the ALLIANCE Myeloma Committee (Chair), the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the American Society of Transplant & Cellular Therapy, and the National Cancer Institute Myeloma Steering Committee. Dr Usmani has served as the Vice-Chair of the SWOG Myeloma Committee, and has served as chair for the ASH Scientific Committee on Plasma Cell Neoplasia and the ASCO Scientific Committee on Plasma Cell Disorders.
Dr Usmani has received several international awards recognizing his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research, COMY Award for Excellence in Myeloma Research, Leukemia & Lymphoma Society Scholar in Clinical Research, and the International Myeloma Society Bart Barlogie Award for Clinical and Translational Research. He has also authored/co-authored more than 210 peer-reviewed research manuscripts and 250 abstracts at national and international meetings.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and The Leukemia & Lymphoma Society. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Saad Z. Usmani, MD, MBA, FACP, has relevant financial relationships with AbbVie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen Pharmaceuticals, Oncopeptides, Sanofi, Seagen Inc., formerly Seattle Genetics, Inc., Secura Bio, Inc., SkylineDX, Takeda, TeneoBio (Consultant); Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen Pharmaceuticals, Merck, Pharmacyclics, Sanofi, Seagen Inc., formerly Seattle Genetics, Inc., SkylineDX, Takeda (Grant/Research Support); Amgen, BMS, Janssen Pharmaceuticals, Sanofi (Other, Speaker).
All of the relevant financial relationships listed for this individual have been mitigated according to RMEI policies.
Planners and Managers
All planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
Instructions for Participation and Credit
In order to receive credit, users must:
- Read the learning objectives and faculty disclosure
- Participate in the activity
- Complete the activity evaluation
A statement of credit will be available to print immediately.
There is no fee to participate.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Contact Information
If you have questions about this activity, please contact RMEI at contact@rmei.com.